5,789 reports of this reaction
17.4% of all CONJUGATED ESTROGENS AND MEDROXYPROGESTERONE ACETATE reports
#2 most reported adverse reaction
BREAST CANCER FEMALE is the #2 most commonly reported adverse reaction for CONJUGATED ESTROGENS AND MEDROXYPROGESTERONE ACETATE, manufactured by Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.. There are 5,789 FDA adverse event reports linking CONJUGATED ESTROGENS AND MEDROXYPROGESTERONE ACETATE to BREAST CANCER FEMALE. This represents approximately 17.4% of all 33,191 adverse event reports for this drug.
Patients taking CONJUGATED ESTROGENS AND MEDROXYPROGESTERONE ACETATE who experience breast cancer female should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
BREAST CANCER FEMALE is a frequently reported adverse event for CONJUGATED ESTROGENS AND MEDROXYPROGESTERONE ACETATE, accounting for a significant proportion of all reports.
In addition to breast cancer female, the following adverse reactions have been reported for CONJUGATED ESTROGENS AND MEDROXYPROGESTERONE ACETATE:
The following drugs have also been linked to breast cancer female in FDA adverse event reports:
BREAST CANCER FEMALE has been reported as an adverse event in 5,789 FDA reports for CONJUGATED ESTROGENS AND MEDROXYPROGESTERONE ACETATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
BREAST CANCER FEMALE accounts for approximately 17.4% of all adverse event reports for CONJUGATED ESTROGENS AND MEDROXYPROGESTERONE ACETATE, making it one of the most commonly reported side effect.
If you experience breast cancer female while taking CONJUGATED ESTROGENS AND MEDROXYPROGESTERONE ACETATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.